Eisai Clinical Trials
Study Overview
E2086
N/A
NCT06462404
Jun 2024 - Mar 2025
Narcolepsy Type 1
1. Mean Sleep Latency (MSL) as Assessed by the 4 Maintenance of Wakefulness Tests (MWTs) for E2086 Versus Placebo at Day 1 [Time Frame: At Day 1]
2. MSL as Assessed by the 4 MWTs for E2086 Versus Placebo at Day 5 [Time Frame: At Day 5]
3. MSL as Assessed by the 4 MWTs for E2086 Versus Placebo at Day 9 [Time Frame: At Day 9]
4. MSL as Assessed by the 4 MWTs for E2086 Versus Placebo at Day 13 [Time Frame: At Day 13]
2. MSL as Assessed by the 4 MWTs for E2086 Versus Placebo at Day 5 [Time Frame: At Day 5]
3. MSL as Assessed by the 4 MWTs for E2086 Versus Placebo at Day 9 [Time Frame: At Day 9]
4. MSL as Assessed by the 4 MWTs for E2086 Versus Placebo at Day 13 [Time Frame: At Day 13]
-
Males and females 18 Years and older (Adult, Older Adult)
-
Completed -
Phase 1
Canada, United States See moreData Sharing
ClinicalStudyDataRequest.com (CSDR) is a multi sponsor site through which qualified researchers who wish to access clinical trial data and associated information in order to conduct further research can submit their research proposal or enquiry.
CSDR Sharing is not available for this study.
CSDR Availability Clinical Trial Data Redacted documents may be available upon request for this study.
Document type Availability Protocol SAP Sample CRF Full CSR